A clinical trial to assess the safety and effectiveness of a new medication called JNJ-63733657 in the treatment of early Alzheimer’s Disease

Occurring Dates
Participant Duration
Appointments at our Malvern clinic every 4 weeks (+/- 1 week) for 2.5 years. The length of the appointments will vary from 2 hours to 3 hours.
State of study

JNJ-63733657 is an laboratory-produced antibody which is designed to recognise and bind to a protein called "tau". Tau is a protein that builds up in the brain and may cause memory loss. This trial will determine if this antibody may prevent tau from spreading in the brain and slow memory loss/cognitive and functional decline.

This study has been approved by Belberry Human research Ethics committee (2020-07-696)

Participation details

We are seeking participants who meet the following criteria:

  • have early Alzheimer’s disease
  • be between 55 and 80 years old (inclusive).
  • have a study partner (a next of kin or someone you have a close relationship to), who is willing to take part in the study and share information about you
  • if taking an approved Alzheimer's disease treatment, must be on a stable dose of that medication for at least 2 months
  • live in Victoria and can attend a clinic in Malvern

If you are interested in participating or would like more information please contact A/Prof Stephen Macfarlane (details below)

Study Address
Level 1, 322 Glenferrie Road, Malvern VIC 3144
Full Name
A/Prof Stephen Macfarlane
HammondCare Malvern
Phone Number
09 9597 6518